Day One Biopharmaceuticals pops nearly 70% after IPO (Nasdaq:DAWN)

Child-cancer drug firm Day One Biopharmaceuticals (Nasdaq:DAWN) popped nearly 70% intraday Thursday on its first trading day following its IPO.
Read More